<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620681</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20042</org_study_id>
    <secondary_id>G6095</secondary_id>
    <nct_id>NCT04620681</nct_id>
  </id_info>
  <brief_title>CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML</brief_title>
  <official_title>CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety of an investigational treatment for&#xD;
      myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine)&#xD;
      stops working or after progression of MDS to acute myeloid leukemia (AML). Funding source -&#xD;
      FDA OOPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to determine the safety of an investigational treatment for&#xD;
      myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine)&#xD;
      stops working or after progression of MDS to acute myeloid leukemia (AML).&#xD;
&#xD;
      Patients with advanced MDS are treated with hypomethylating agents (HMAs) such as azacitidine&#xD;
      or decitabine. These medications can be effective for a few months to a few years, but&#xD;
      usually lose effect eventually. This study is attempting to design a therapy called&#xD;
      &quot;non-engrafting, CD8 depleted donor lymphocyte infusion&quot; or &quot;NE-DLI&quot; as a treatment for these&#xD;
      diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of CD8 depleted non-engrafting HLA-mismatched unrelated donor lymphocytes infusion (NE-DLI)</measure>
    <time_frame>Up to 60 days per dose level</time_frame>
    <description>Maximum Tolerated Dose will be determined by testing increasing doses of CD8 depleted non-engrafting HLA-mismatched unrelated donor lymphocytes infusion (NE-DLI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Overall Response Rate is defined as Complete Response + Partial Response using RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Progression Free Survival is defined as the time from enrollment to date of progression or death, or censor at last follow-up date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Overall Survival is defined as the time from study enrollment to death from any cause or censored at last follow up date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Hematologic response will be determined using International Working Group 2006 criteria for MDS patients and the International Working Group 2003 criteria for AML</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 1: 1X10^6 CD4 T Cells/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 2: 1X10^7 CD4 T Cells/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at dose level 3: 5 X10^7 CD4 T Cells/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 -Treatment at Maximum Tolerated Dose (MTD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive cytotoxic induction chemotherapy with a standard of care cytarabine-based regimen. 24-36 hours after chemotherapy cessation, participants will receive CD8-depleted non-engrafting HLA-mismatched unrelated donor lymphocyte infusion (NE-DLI) at MTD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes</intervention_name>
    <description>Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent</description>
    <arm_group_label>Phase 1 Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1 Dose Level 2</arm_group_label>
    <arm_group_label>Phase 1 Dose Level 3</arm_group_label>
    <arm_group_label>Phase 2 -Treatment at Maximum Tolerated Dose (MTD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care Chemotherapy</intervention_name>
    <description>Standard of care cytarabine-based chemotherapy</description>
    <arm_group_label>Phase 1 Dose Level 1</arm_group_label>
    <arm_group_label>Phase 1 Dose Level 2</arm_group_label>
    <arm_group_label>Phase 1 Dose Level 3</arm_group_label>
    <arm_group_label>Phase 2 -Treatment at Maximum Tolerated Dose (MTD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Myelodysplastic Syndrome (MDS) having failed hypomethylating agent (HMA) therapy cohort:&#xD;
&#xD;
          -  Age 18-79 years, inclusive&#xD;
&#xD;
          -  Pathologically confirmed MDS or myelodysplastic/myeloproliferative overlap (MDS/MPN)&#xD;
&#xD;
          -  IPSS-R score intermediate, high or very high&#xD;
&#xD;
          -  Must have failed therapy with an HMA (defined as lack of response by International&#xD;
             Working Group criteria (1) or intolerance of the drug)&#xD;
&#xD;
        Secondary Acute Myeloid Leukemia (sAML):&#xD;
&#xD;
          -  Pathologically confirmed AML according to World Health Organization (WHO) criteria&#xD;
&#xD;
          -  Evidence of an antecedent hematologic disorder (AHD) prior to acute leukemia including&#xD;
             a known prior diagnosis of MDS, MPN or MDS/MPN or data suggestive of an AHD such as&#xD;
             cytopenias, fibrosis, macrocytic anemia, cellular or dysplasia at or prior to the time&#xD;
             of diagnosis. If available, MDS-defining karyotypes (-7/del(7q), -5/del(5q), del(13q),&#xD;
             del(11q), del(12p), t(12p), del(9q), idic(X)(q13), t(17p) (unbalanced translocations)&#xD;
             or i(17q) (ie, loss of 17p), t(11;16)(q23;p13.3), t(3;21)(q26.2;q22.1),&#xD;
             t(1;3)(p36.3;q21), t(2;11)(p21;q23), inv(3)(q21q26.2), t(6;9)(p23;q34)) or somatic&#xD;
             mutations in multiple genes including p53, TET2, JAK2, CALR, MPL, ASXL1, RUNX1, SRSF2,&#xD;
             SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 would also confirm eligibility.&#xD;
&#xD;
          -  Age 60-79 years, inclusive&#xD;
&#xD;
          -  May be previously untreated&#xD;
&#xD;
        For both cohorts:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          -  Deemed eligible to receive cytotoxic chemotherapy&#xD;
&#xD;
          -  Creatinine clearance (CrCl)&gt;50ml/min&#xD;
&#xD;
          -  Total bilirubin &lt;2 mg/dL (except for patients with Gilbert's disease), AST and ALT &lt;&#xD;
             3x ULN&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction ≥ 50%&#xD;
&#xD;
          -  Willing and able to participate in study assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had systemic chemotherapy or radiotherapy within 4 weeks (6 weeks&#xD;
             for nitrosoureas or mitomycin C) prior to entering the study or those who have not&#xD;
             recovered from adverse events due to agents administered more than 4 weeks earlier.&#xD;
             Hydroxyurea during this period may be given as a bridging therapy to maintain disease&#xD;
             stability while awaiting treatment. Intrathecal chemotherapy within this time frame is&#xD;
             permitted. Intrathecal chemotherapy may be continued during protocol therapy in order&#xD;
             to consolidate or maintain a central nervous system (CNS) remission, but not to treat&#xD;
             active CNS disease&#xD;
&#xD;
          -  Acute promyelocytic leukemia, or the presence of t(15;17)&#xD;
&#xD;
          -  Patients receiving any other investigational agents&#xD;
&#xD;
          -  Uncontrolled concurrent illness including, but not limited to, ongoing and&#xD;
             uncontrolled infection, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study because there is an unknown but potential&#xD;
             risk for adverse events in the fetus. Breastfeeding should be discontinued if the&#xD;
             mother is treated. These potential risks may also apply to other agents used in this&#xD;
             study&#xD;
&#xD;
          -  Patients who have any debilitating medical or psychiatric illness that would preclude&#xD;
             their giving informed consent or their receiving optimal treatment and follow-up&#xD;
&#xD;
          -  Patients with a poor functional status of ECOG 3-4, or otherwise deemed unfit to&#xD;
             tolerate induction chemotherapy.&#xD;
&#xD;
          -  Patients with blastic transformation of chronic myelogenous leukemia are ineligible&#xD;
&#xD;
          -  Exposure to a humanized mouse chimeric antibody, as this could sensitize patients to&#xD;
             components of the CD8 depletion column that may be present in small amounts in the&#xD;
             cell product&#xD;
&#xD;
          -  Prior allogenic hematopoietic cell transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hany Elmariah, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Edelman</last_name>
      <phone>813-745-1040</phone>
      <email>Jeffrey.Edelman@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Hany Elmariah, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nelli Bejanyan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Davila, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farhad Khimani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rami Komrokji, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Kuykendall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Lancet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Padron, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Sallman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chetasi Talati, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>sAML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

